Avadel
Clinical trials sponsored by Avadel, explained in plain language.
A biopharmaceutical company focused on central nervous system disorders.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New nightly pill aims to tame daytime sleepiness in rare sleep disorder
Symptom relief CompletedThis study tested a once-nightly extended-release form of sodium oxybate (FT218) in 157 adults with idiopathic hypersomnia, a condition causing excessive daytime sleepiness despite adequate sleep. Participants were already on stable doses of stimulants or other alerting agents. T…
Phase: PHASE3 • Sponsor: Avadel • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
New sleep drug shows promise for narcolepsy patients
Symptom relief CompletedThis study followed 71 adults with narcolepsy who started taking LUMRYZ, a medication for excessive daytime sleepiness. Over 4 months, participants filled out questionnaires about their symptoms, how they felt about the drug, and their quality of life. The goal was to see if LUMR…
Sponsor: Avadel • Aim: Symptom relief
Last updated Jun 27, 2026 09:04 UTC
-
New Once-Nightly pill could simplify narcolepsy treatment
Symptom relief CompletedThis study tested a new once-nightly medication called FT218 for people with narcolepsy who experience excessive daytime sleepiness and sudden muscle weakness (cataplexy). It included 184 participants, some already on a twice-nightly medication and some new to treatment. The goal…
Phase: PHASE3 • Sponsor: Avadel • Aim: Symptom relief
Last updated Jun 27, 2026 07:53 UTC